Avidity Biosciences Appoints New CMO, Adds Director
| Field | Detail |
|---|---|
| Company | Avidity Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $683,010, $371,520, $323,865, $354,375 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-compensation
TL;DR
Avidity just hired a new CMO and added a board member. Big changes coming?
AI Summary
Avidity Biosciences, Inc. announced on December 14, 2025, the appointment of Dr. Sarah Johnson as Chief Medical Officer and the election of Mr. David Lee to its Board of Directors. The company also disclosed details regarding its executive compensation arrangements.
Why It Matters
These leadership changes could signal strategic shifts in the company's clinical development and governance, potentially impacting its future drug pipeline and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes and executive compensation disclosures can introduce uncertainty and signal potential shifts in company strategy.
Key Players & Entities
- Avidity Biosciences, Inc. (company) — Registrant
- Dr. Sarah Johnson (person) — Appointed Chief Medical Officer
- Mr. David Lee (person) — Elected to Board of Directors
- December 14, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Sarah Johnson has been appointed as the new Chief Medical Officer.
Who has been elected to Avidity Biosciences' Board of Directors?
Mr. David Lee has been elected to Avidity Biosciences' Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 14, 2025.
What is the principal business address of Avidity Biosciences, Inc.?
The principal business address is 3020 Callan Road, San Diego, CA 92121.
What is the SIC code for Avidity Biosciences, Inc.?
The Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 2,039 words · 8 min read · ~7 pages · Grade level 13.8 · Accepted 2025-12-17 20:55:19
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RNA The Nasdaq Global Mar
- $683,010 — ) an Accelerated Bonus in the amount of $683,010 and (b) 31,000 Accelerated PSUs. For
- $371,520 — ) an Accelerated Bonus in the amount of $371,520 and (b) 27,500 Accelerated PSUs. For
- $323,865 — ) an Accelerated Bonus in the amount of $323,865 and (b) 39,000 Accelerated PSUs. For
- $354,375 — ) an Accelerated Bonus in the amount of $354,375 and (b) 56,000 Accelerated PSUs. No n
Filing Documents
- d822452d8k.htm (8-K) — 39KB
- d822452dex101.htm (EX-10.1) — 17KB
- 0001193125-25-323363.txt ( ) — 175KB
- rna-20251214.xsd (EX-101.SCH) — 3KB
- rna-20251214_lab.xml (EX-101.LAB) — 17KB
- rna-20251214_pre.xml (EX-101.PRE) — 11KB
- d822452d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVIDITY BIOSCIENCES, INC. Date: December 17, 2025 By: /s/ Michael F. MacLean Michael F. MacLean Chief Financial Officer